ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

CAR T Cell Therapies for ALL and NHL

Marcel R.M. van den Brink, MD, PhD
Published Online: 11:19 AM, Tue December 2, 2014
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.

Clinical Pearls

  • A phase I study will be presented at ASH evaluating CAR T cell therapy directed against CD19 for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
  • Another phase I study evaluated high dose therapy and ASCT followed by CAR T cell therapy directed against CD19 for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.


Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.